AAHRPP Awards Accreditation to King Abdullah International Medical Research Center (KAIMRC)
03 Jul 2023
Clinical Study
WASHINGTON, July 3, 2023 /PRNewswire/ -- The Association for the Accreditation of Human Research Protection Programs has accredited
King Abdullah International Medical Research Center (KAIMRC), a leading research center with physical presence in Riyadh, Jeddah, and Al-Aḥsa, Saudi Arabia.
KAIMRC is the third organization in Saudi Arabia to achieve AAHRPP accreditation. "Protecting research participants is a worldwide goal, one which AAHRPP accreditation recognizes. In achieving AAHRPP accreditation, KAIMRC has demonstrated its dedication to this important objective," AAHRPP President and CEO Elyse I. Summers said. "With each accreditation, we are adding to our global network of organizations that share a commitment to high-quality, ethical research."
AAHRPP has accredited more than 600 research entities across the U.S. and in Australia, Belgium, Brazil, Canada, China, India, Japan, Jordan, Mexico, Republic of Korea, Saudi Arabia, Singapore, Taiwan, and Thailand.
All major U.S. independent institutional review boards have earned AAHRPP accreditation. In addition, more than 85% of the top U.S. National Institutes of Health-funded academic medical centers and 70% of U.S. medical colleges are AAHRPP-accredited or have begun the accreditation process.
Research institutes, clinical research centers, and community hospitals also are among those that have attained accreditation.
About AAHRPP: A nonprofit organization, AAHRPP provides accreditation for organizations that conduct or review human research and can demonstrate that their protections exceed the safeguards required by the international guidelines and laws governing research involving humans in the U.S. and other countries. To learn more, visit www.aahrpp.org.
FOR MORE INFORMATION CONTACT:
Michelle Feige
Executive Vice President
[email protected]
202-783-1112
SOURCE Association for the Accreditation of Human Research Protection Programs
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.